MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
67.82
+0.71 (1.06%)
At close: Aug 7, 2026, 4:00 PM EDT
67.70
-0.12 (-0.18%)
Pre-market: Aug 10, 2026, 4:13 AM EDT
MBX Biosciences Employees
MBX Biosciences had 63 employees as of December 31, 2025. The number of employees increased by 20 or 46.51% compared to the previous year.
Employees
63
Change (1Y)
20
Growth (1Y)
46.51%
Revenue / Employee
n/a
Profits / Employee
-$1,655,429
Market Cap
3.27B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 63 | 20 | 46.51% |
| Dec 31, 2024 | 43 | 16 | 59.26% |
| Sep 30, 2024 | 38 | 11 | 40.74% |
| Jun 30, 2024 | 36 | - | - |
| Mar 31, 2024 | 28 | - | - |
| Dec 31, 2023 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Arcus Biosciences | 601 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Alumis | 227 |
| uniQure | 221 |
| Immunome | 206 |
| Celldex Therapeutics | 198 |
MBX News
- 2 days ago - MBX Biosciences price target raised to $88 from $70 at Barclays - TheFly
- 3 days ago - MBX Biosciences reports Q2 EPS (78c), consensus (59c) - TheFly
- 3 days ago - MBX Biosciences Earnings release: Q2 2026 - Filings
- 3 days ago - MBX Biosciences Quarterly report: Q2 2026 - Filings
- 4 days ago - MBX Biosciences Slides: Corporate presentation - Filings
- 11 days ago - MBX Biosciences price target raised to $91 from $57 at Mizuho - TheFly
- 17 days ago - MBX Biosciences price target raised to $90 from $60 at UBS - TheFly
- 27 days ago - MBX Biosciences CEO Kent Hawryluk steps down, Steve Hoerter succeeds - TheFly